Bristol Myers Squibb is expanding its scope in cancer by acquiring rights to a Phase 1-ready Orum Therapeutics program that brings a new twist to antibody drug conjugates. The deal is the latest business development move in the hot field of ADCs.
BMS Pays $100M for Next-Gen Orum Therapeutics ADC for Blood Cancers
